Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Leukemia

Free Subscription 16.03.2026 4 Am J Hematol 1 Ann Hematol 7 Blood 5 Bone Marrow Transplant 4 Br J Haematol 2 Cancer 1 Eur J Haematol 1 Hematol Oncol Clin North Am 3 Int J Hematol 1 J Pediatr Hematol Oncol 2 Leuk Lymphoma 4 Leuk Res 10 Leukemia

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. BALL S, Awan FT, Tomlinson BK, Stopczynski T, et al
   Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
   Am J Hematol. 2026 Mar 8. doi: 10.1002/ajh.70266.
   PubMed         Abstract available
   
   
2. ZHOU X, Mu Q, Chen H, Chen Y, et al
   Torque Teno Virus Drives Atypical Acute Promyelocytic Leukemia as a Novel Molecular Subtype.
   Am J Hematol. 2026 Mar 7. doi: 10.1002/ajh.70276.
   PubMed        
   
   
3. ZAMBROTTA GPM, Nicolini FE, Assouline S, Busque L, et al
   Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
   Am J Hematol. 2023;98:1762-1771.
   PubMed         Abstract available
   
   
4. PLEYER L, Vaisband M, Drost M, Pfeilstocker M, et al
   Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
   Am J Hematol. 2023;98:1685-1698.
   PubMed         Abstract available
   
   

   
   Ann Hematol

5. SUN Y, Qin S, Wang L, Yi H, et al
   The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis.
   Ann Hematol. 2026;105:168.
   PubMed         Abstract available
   
   

   
   Blood

6. RHEIN S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, et al
   A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.
   Blood. 2026;147:1058-1069.
   PubMed         Abstract available
   
   
7. KNAPPER S, Dillon LW, Babu M, Thomas A, et al
   CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.
   Blood. 2026;147:1048-1057.
   PubMed         Abstract available
   
   
8. PLATZBECKER AS, Georgi JA, Middeke JM, Sockel K, et al
   Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
   Blood. 2026;147:1098-1110.
   PubMed         Abstract available
   
   
9. MEYER E, Salhotra A, Gandhi A, Pantin J, et al
   Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.
   Blood. 2025 Dec 12:blood.2025031313. doi: 10.1182/blood.2025031313.
   PubMed         Abstract available
   
   
10. MUJOLLARI J, Estruch M, Khadgawat P, Choudhary S, et al
    The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.
    Blood. 2026;147:1229-1236.
    PubMed         Abstract available
    
    
11. DI GIACOMO D, Polonen P, Bardelli V, Kimura S, et al
    Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.
    Blood. 2026 Mar 6:blood.2025031402. doi: 10.1182/blood.2025031402.
    PubMed         Abstract available
    
    
12. DERMER K, Richardson AI
    Pediatric acute erythroid leukemia with NUP98::KDM5A fusion.
    Blood. 2026;147:1237.
    PubMed        
    
    

    
    Bone Marrow Transplant

13. BUG G, Labopin M, Byrne JL, Mielke S, et al
    Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first
    Bone Marrow Transplant. 2026 Mar 6. doi: 10.1038/s41409-026-02805.
    PubMed         Abstract available
    
    
14. ABOU DALLE I, Galimard JE, Poire X, Sanz J, et al
    The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.
    Bone Marrow Transplant. 2026;61:326-332.
    PubMed         Abstract available
    
    
15. RIEGER MJ, Stolz SM, Muller AM, Schwotzer R, et al
    Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm.
    Bone Marrow Transplant. 2023;58:1121-1129.
    PubMed         Abstract available
    
    
16. YANADA M, Shimomura Y, Mizuno S, Matsuda K, et al
    External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia.
    Bone Marrow Transplant. 2023;58:1096-1103.
    PubMed         Abstract available
    
    
17. GAVRIILAKI E, Sakellari I, Labopin M, Bornhauser M, et al
    Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Ac
    Bone Marrow Transplant. 2023;58:1084-1088.
    PubMed         Abstract available
    
    

    
    Br J Haematol

18. HILLS RK
    Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.
    Br J Haematol. 2023;203:353-354.
    PubMed         Abstract available
    
    
19. NOOR S, Haidary AM, Yosufzai AW, Niazai M, et al
    Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan.
    Br J Haematol. 2023;203:404-410.
    PubMed         Abstract available
    
    
20. MOIA R, Terzi di Bergamo L, Talotta D, Bomben R, et al
    XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
    Br J Haematol. 2023;203:416-425.
    PubMed         Abstract available
    
    
21. APOSTOLOVA P, Kreutmair S, Toffalori C, Punta M, et al
    Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
    Br J Haematol. 2023;203:264-281.
    PubMed         Abstract available
    
    

    
    Cancer

22. GUPTA DG, Varma N, Sharma P, Truica MI, et al
    Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.
    Cancer. 2023;129:3390-3404.
    PubMed         Abstract available
    
    
23. 
    Correction to "Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia".
    Cancer. 2026;132:e70347.
    PubMed        
    
    

    
    Eur J Haematol

24. MOLICA S, Allsup D
    Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.
    Eur J Haematol. 2026 Mar 12. doi: 10.1111/ejh.70160.
    PubMed         Abstract available
    
    

    
    Hematol Oncol Clin North Am

25. CUMMINS K, Gill S
    Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Hematol Oncol Clin North Am. 2023;37:1125-1147.
    PubMed         Abstract available
    
    

    
    Int J Hematol

26. TSUTSUMI H, Inoshita N, Tanabe N, Sekiguchi Y, et al
    Central nervous system involvement in plasma cell neoplasms: a rare presentation illustrated by three cases.
    Int J Hematol. 2026;123:459-465.
    PubMed         Abstract available
    
    
27. TAKIZAWA J, Yoshida I, Ogawa Y, Toubai T, et al
    A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL.
    Int J Hematol. 2026;123:375-384.
    PubMed         Abstract available
    
    
28. SAIKA W, Yamazaki H, Tanaka S, Lin M, et al
    BRD9 depletion-mediated ALOX5 upregulation via chromatin dysregulation induces ferroptosis in SF3B1-mutant hematopoiesis.
    Int J Hematol. 2026;123:342-355.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

29. PINEAU O, Mollevi C, Dutron S, Bret C, et al
    Infectious Complications in Children, Adolescents, and Young Adults Treated for Acute Leukemia and Lymphoblastic Lymphoma: A Single-Center Experience.
    J Pediatr Hematol Oncol. 2026 Feb 23. doi: 10.1097/MPH.0000000000003175.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

30. GUOLO F, Del Sette P, Riccardi F, Ballerini F, et al
    Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications.
    Leuk Lymphoma. 2026 Mar 7:1-7. doi: 10.1080/10428194.2026.2634180.
    PubMed         Abstract available
    
    
31. SIMKHADA S, Acharya L, Loeffler B, Ravindra A, et al
    Improved overall survival in acute myeloid leukemia over the last 15 years.
    Leuk Lymphoma. 2026 Mar 7:1-9. doi: 10.1080/10428194.2026.2635662.
    PubMed         Abstract available
    
    

    
    Leuk Res

32. BHATTACHARJEE U, Jandial A, Singh C, Lekshmon KS, et al
    Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
    Leuk Res. 2023;133:107367.
    PubMed         Abstract available
    
    
33. DE LA GARZA-SALAZAR F, Colunga-Pedraza PR, Gomez-Almaguer D, Garcia-Zarate VA, et al
    Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study.
    Leuk Res. 2023;133:107373.
    PubMed         Abstract available
    
    
34. TSERTSVADZE T, Edwards K, John-Olabode S, Datikashvili-David I, et al
    Expression and signaling patterns of CD180/MD-1 and CD150 in Chronic Lymphocytic Leukaemia (CLL) cells.
    Leuk Res. 2026;162:108169.
    PubMed         Abstract available
    
    
35. HOU HA, Getta B, Ahn JS, Elsouda D, et al
    Outcomes of patients with R/R FLT3(mut+) AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation.
    Leuk Res. 2026;162:108186.
    PubMed         Abstract available
    
    

    
    Leukemia

36. ZHANG L, Han Q, Xiang H, Lapalombella R, et al
    Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leukemia. 2026 Mar 6. doi: 10.1038/s41375-026-02898.
    PubMed         Abstract available
    
    
37. TIONG IS, Hunter S, Kankanige Y, Mehta NN, et al
    Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.
    Leukemia. 2026;40:649-660.
    PubMed         Abstract available
    
    
38. GUO Y, Sui P, Yang H, Zhu G, et al
    Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.
    Leukemia. 2026;40:594-608.
    PubMed         Abstract available
    
    
39. SOBERON V, Osswald L, Moore A, Sosnowska D, et al
    Strong constitutive NF-kappaB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.
    Leukemia. 2026;40:522-539.
    PubMed         Abstract available
    
    
40. CAMIOLO G, Gonzalez Silvera D, Leah T, Schwaller J, et al
    CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.
    Leukemia. 2026;40:540-552.
    PubMed         Abstract available
    
    
41. CHONABAYASHI K, Iwasaki M, Kanda J, Takamori H, et al
    NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.
    Leukemia. 2026;40:491-501.
    PubMed         Abstract available
    
    
42. SMALLBONE P, Cao K, Saliba RM, Carmarzzi Y, et al
    Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.
    Leukemia. 2026 Mar 9. doi: 10.1038/s41375-026-02907.
    PubMed         Abstract available
    
    
43. SELIMOGLU-BUET D, Chevret S, Santini V, Thepot S, et al
    Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?
    Leukemia. 2026 Mar 9. doi: 10.1038/s41375-026-02901.
    PubMed         Abstract available
    
    
44. LOGHAVI S, Farhat A, Jamison TJ, El Hajjar G, et al
    Immunophenotypic changes following menin inhibition in acute myeloid leukemia.
    Leukemia. 2026 Mar 11. doi: 10.1038/s41375-026-02905.
    PubMed         Abstract available
    
    
45. PARKER H, Carr L, Norris K, Nilsson-Takeuchi A, et al
    High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.
    Leukemia. 2026 Mar 11. doi: 10.1038/s41375-026-02906.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum